Catherine Lee, MD, University of Utah, Salt Lake City, UT, comments on the challenges associated with the use of novel therapies for treatment-refractory chronic graft-versus-host disease (TR-cGvHD). Dr Lee explains that cGvHD is highly heterogeneous and further randomized controlled trials are required to help determine which agents are suitable for different groups of patients. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.